Clinical trial
Phase II Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management…
NCT00216658 · Janssen Pharmaceutical K.K., Industry · Completed
Key facts
| NCT number | NCT00216658 |
|---|---|
| Title | Phase II Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Cancer Pain- Assessment of Effectiveness, Safety and Pharmacokinetics - |
| Official title | Open Label Study to Confirm Effectiveness, Safety and Pharmacokinetics of Fentanyl Transdermal Matrix Patch, in Japanese Patients With Cancer Pain Who Have Had a Minimum Amount of Morphine Therapy, Such as Equal to Less Than 45 mg/Day of Oral Morphine or Oxycodone Equal to Less Than 30 mg/Day. |
| Lead sponsor | Janssen Pharmaceutical K.K., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pain, Intractable |
| Intervention type | Drug |
| Interventions | fentanyl |
| Enrollment | 87 |
| Start date | Dec 1, 2004 |
| Completion | Sep 1, 2005 |
| First posted | Sep 22, 2005 |
| Last update posted | Jan 24, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: